Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 <scp>MEASURE</scp> 3 Study
Distribution of the number of citations over years.